Name: 글로벌 시장 동향
SKU: MD7731
Availability: InStock

보고서 요약(국문)

개요
글로벌 스마트 인슐린 관리 기기 시장은 2022년 XX백만 달러 규모에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률로 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
스마트 인슐린 관리 기기는 제1형, 제2형, 임신성 당뇨병을 포함한 다양한 당뇨병 관리에 사용됩니다. 이러한 기기는 기술적으로 발전되어 있으며, 혈당 측정기, 식사 감지 기능이 있는 스마트 펜 등 여러 기기와 동시에 연결하여 효율성을 높일 수 있습니다. 일부 기기는 재사용이 가능하고 스마트폰 앱과 연동하여 혈당 수치를 지속적으로 모니터링할 수 있습니다.
건강에 대한 사람들의 인식이 높아지고 기기 사용이 간편해짐에 따라, 특히 노년층을 중심으로 스마트 인슐린 관리 기기의 사용이 증가하고 있습니다. 전 세계적으로 당뇨병 유병률은 높습니다. 예를 들어, 미국 국립보건원(NIH)에 따르면 2030년에는 전 세계적으로 6억 4,300만 명이 당뇨병을 앓게 될 것이며, 2045년에는 7억 8,300만 명으로 증가할 것으로 예상됩니다.
시장 동향: 동인 및 제약 요인
기업들의 전략적 개발 증가
당뇨병 및 그 후유증에 대한 인식이 높아짐에 따라 기업들의 전략적 개발이 증가했습니다. 사람들의 건강에 대한 자각이 높아짐에 따라 스마트 인슐린 펜 사용이 증가했으며, 기술 발전 또한 이를 뒷받침하고 있습니다.
예를 들어, 자동 인슐린 투여 분야의 선구자인 디아벨룹(Diabeloop)은 2023년 3월, 세계적인 의료 기업인 노보노디스크(Novo Nordisk)와 협력할 예정입니다. 이 계약은 디아벨룹의 자가 학습 알고리즘인 DBL-4pen™을 노보노디스크의 연결형 재사용 인슐린 펜인 노보펜 6(NovoPen 6) 및 노보펜 에코 플러스(NovoPen Echo Plus)에 통합하는 것을 포함합니다. 디아벨루프(Diabeloop)는 제2형 당뇨병 환자를 대상으로 결합 기술의 효능과 임상적 이점을 평가하기 위한 연구를 계획하고 있습니다.
또한, 2023년 9월 애보트(Abbott)와 빅풋 바이오메디컬(Bigfoot Biomedical)은 당뇨병 환자를 위한 스마트 인슐린 관리 시스템 개발 분야의 선두 기업인 빅풋을 애보트가 인수하는 최종 계약을 체결했습니다.
2023년 5월, 메드트로닉(Medtronic plc)은 튜브가 없고 착용 가능하며 완전히 일회용인 인슐린 전달 장치인 EOPatch를 제조하는 EOFlow Co. Ltd를 인수하는 최종 계약을 체결했습니다.
인슐린 기기 관련 합병증
인슐린 기기를 이용한 당뇨병 관리는 부적절한 사용 및 기기 고장으로 인해 합병증을 유발할 수 있습니다. 소아당뇨병연구재단(Juvenile Diabetes Research Foundation Ltd)의 2023년 논문에 따르면, 인슐린 펌프는 케토산증 발생 가능성을 높여 혈당 수치를 상승시키고 심각한 합병증을 유발할 수 있습니다. 인슐린 펜 바늘은 바늘 찔림 사고를 유발하여 혈액 매개 감염 위험을 높입니다. 농양 형성, 지방비대증, 지방위축증은 인슐린 펜과 주사기에서도 나타날 수 있습니다.
세그먼트 분석
전 세계 스마트 인슐린 관리 기기는 제품 유형, 질병 유형, 최종 사용자 및 지역별로 세분화됩니다.
인슐린 펌프 부문은 시장 점유율의 약 56.7%를 차지했습니다.
스마트 인슐린 펌프의 출시 증가로 인해 인슐린 펌프는 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 예를 들어, 의료 기술 분야의 글로벌 리더인 메드트로닉(Medtronic plc)은 2023년 4월, 스마트가드(SmartGuard) 기술을 적용하여 손가락 채혈 없이 인슐린을 투여할 수 있는 가디언 4(Guardian 4) 센서가 탑재된 미니메드 780G(MiniMed 780G) 시스템에 대해 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다. 이는 식사 감지 기술을 탑재한 세계 최초의 인슐린 펌프입니다.
또한, 베타 바이오닉스(Beta Bionics Inc.)는 2023년 5월, iLet ACE 펌프와 iLet 투약 결정 소프트웨어에 대해 FDA 승인을 받았습니다. 두 기기와 통합 연속 혈당 측정기(iCGM)를 결합하여 iLet 바이오닉 췌장이라는 새로운 시스템을 구성합니다. 이 새로운 자동 인슐린 투여(AID) 시스템은 알고리즘을 사용하여 인슐린 투여량을 결정하고 제어합니다. 이 시스템은 6세 이상 제1형 당뇨병 환자에게 유용합니다.
지역 분석
북미는 2022년 시장 점유율의 약 43.5%를 차지했습니다.
미국 국립 당뇨병 및 신장 질환 연구소(NIDDK)에 따르면, 2023년 미국에서는 매년 약 2%에서 10%의 임신이 임신성 당뇨병의 영향을 받습니다. 임신 중 당뇨병이 발생하는 여성은 50%가 넘습니다.
미국에서 당뇨병 진단에 드는 전체 비용 또한 높습니다. 예를 들어, 미국 질병통제예방센터(CDC)의 2023년 자료에 따르면, 2022년 당뇨병 진단으로 인한 총 예상 비용은 4,130억 달러였으며, 여기에는 직접 의료비 3,070억 달러와 당뇨병 관련 간접 비용 1,060억 달러가 포함됩니다. 2022년 당뇨병 관련 초과 의료비는 1인당 약 12,000달러였습니다.
COVID-19 영향 분석
COVID-19는 스마트 인슐린 관리 기기 시장에 긍정적인 영향을 미쳤습니다. 당뇨병이나 고혈압과 같은 기저 질환이 있는 경우 COVID-19 감염 위험이 높아졌습니다. 이로 인해 당뇨병 관리에 대한 관심과 주의가 더욱 커졌습니다. 감염에 대한 두려움 때문에 많은 사람들이 인슐린 펌프, 주사기, 펜 등의 인슐린 기기를 사용하여 당뇨병을 관리하기 시작했습니다.
시장 세분화
제품 유형별
• 인슐린 펜 주사기
• 인슐린 제트 주사기
• 인슐린 펌프
o 외부 인슐린 펌프
o 이식형 펌프
• 인슐린 패치
• 인슐린 흡입기
질병 유형별
• 제1형 당뇨병
• 제2형 당뇨병
• 임신성 당뇨병
최종 사용자별
• 병원
• 가정 간호 환경
• 전문 클리닉
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 동아프리카
경쟁 환경
스마트 인슐린 관리 기기 시장의 주요 글로벌 업체로는 Sanofi S.A., Abbott Laboratories, Medtronic plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, i-SENS, Inc., Novo Nordisk A/S, Ypsomed Holding AG, Diabeloop SA., Tandem Diabetes Care, Inc. 등이 있습니다.
주요 개발 사항
• 2023년 9월, Medtronic은 InPen 통합 차세대 Simplera(CGM) 연속 혈당 측정기에 대한 CE 마크를 획득했습니다.

• 2022년 9월, Medtronic Plc는 InPen 스마트 인슐린 펜과 Guardian 4 스마트 연속 혈당 측정(CGM) 시스템을 결합하여 스마트 인슐린 투여를 제공하는 Smart MDI 시스템을 출시했습니다.
보고서 구매 이유

• 제품 유형, 질병 유형, 최종 사용자 및 지역별 글로벌 스마트 인슐린 관리 기기 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위해. • 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 스마트 인슐린 관리 기기 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 스마트 인슐린 관리 기기 시장 보고서는 약 58개의 표, 60개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Smart Insulin Management Devices Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
Smart insulin management devices are used for managing diabetes which includes type 1, type 2, and gestational diabetes. These devices are technologically advanced and can be connected to multiple devices like glucose monitors, and smart pens with meal detection technology all at once so that the efficiency increases. Few of the devices are reusable and can be connected to a smartphone app so that continuous monitoring of blood sugar levels won't be difficult.
The increase in awareness about health among people along with the easy usage of the devices increased the overall usage by people, especially the geriatric population. The prevalence of diabetes worldwide is high for instance, according to the National Institute of Health, by 2030, 643 million people will have diabetes globally, increasing to 783 million by 2045.
Market Dynamics: Drivers & Restraints
Increasing strategic developments by the companies
The number of strategic developments by the companies increased due to the increase in awareness about diabetes and its aftereffects. People are becoming self-aware about health hence the usage of smart insulin pens increased combined with technological advancements.
For instance, in March 2023, Diabeloop, a pioneer in Automated Insulin Delivery, will collaborate with a leading global healthcare company, Novo Nordisk. The agreement covers integrating DBL-4penTM, Diabeloop’s self-learning algorithm for MDI therapy, with Novo Nordisk’s connected and reusable insulin pens, NovoPen 6, and NovoPen Echo Plus. Diabeloop is planning a dedicated study for people living with Type 2 diabetes to evaluate the efficacy and clinical benefits of the combined technologies.
Furthermore, in September 2023, Abbott and Bigfoot Biomedical entered into a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.
In May 2023, Medtronic plc entered into a set of definitive agreements to acquire EOFlow Co. Ltd, manufacturer of the EOPatch device, a tubeless, wearable, and fully disposable insulin delivery device.
Complications associated with insulin devices
Management of diabetes using insulin devices causes complications due to the lack of proper usage and device failures. According to the Juvenile Diabetes Research Foundation Ltd, 2023 article, insulin pumps increase the chances of ketoacidosis which can increase the glucose level and cause severe other complications. The risk of transmitting bloodborne infections is higher with insulin pen needles which cause needle stick injuries. Abscess formation, lipohypertrophy, and lipoatrophy are also seen with insulin pens and injectors.
Segment Analysis
The global smart insulin management devices are segmented based on product type, disease type, end user and region.
The Insulin Pumps segment accounted for approximately 56.7% of the market share
Insulin pumps are expected to hold the largest share of the market due to the increased launch of smart insulin pumps. For instance, in April 2023, Medtronic plc, the global leader in medical technology, stated the U.S. Food and Drug Administration (FDA) approval of its MiniMed 780G system with the Guardian 4 sensor requiring no fingersticks while in SmartGuard technology. It is the world's first insulin pump with meal-detection technology.
Furthermore, in May 2023, Beta Bionics Inc. received Food and Drug Administration clearance for iLet ACE Pump and iLet Dosing Decision Software. The two devices along with an integrated continuous glucose monitor (iCGM), will form a new system called the iLet Bionic Pancreas. This new automated insulin dosing (AID) system uses an algorithm to determine and command insulin delivery. It is useful for people six years of age and older with type 1 diabetes.
Geographical Analysis
North America accounted for approximately 43.5% of the market share in 2022
According to National Institute of Diabetes and Kidney Diseases, 2023, approximately 2% to 10% of pregnancies in the United States are affected by gestational diabetes annually. More than 50% of women develop diabetes during their pregnancies.
The overall cost of diagnosing diabetes is also high in the US. For instance, according to Centers for Disease Control and Prevention, 2023, the total estimated cost of diagnosed diabetes in 2022 was $413 billion, including $307 billion in direct medical costs and $106 billion in indirect costs attributable to diabetes. Excess medical costs associated with diabetes were about $12,000 per person in 2022.
COVID-19 Impact Analysis
COVID-19 has impacted positively the smart insulin management devices market. There is an increased risk of contracting COVID-19 with underlying co-morbidities such as diabetes and hypertension. This shifted the focus of managing diabetes with care and caution. Due to the fear of contracting the infection, many people started to manage diabetes with the help of insulin devices like pumps, injectors, pens, etc.
Market Segmentation
By Product Type
• Insulin Pen Injectors
• Insulin jet injectors
• Insulin Pumps
o External Insulin pumps
o Implantable pumps
• Insulin patches
• Insulin inhalers
By Disease Type
• Diabetes Type I
• Diabetes Type II
• Gestational Diabetes
By End User
• Hospitals
• Home Care settings
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the smart insulin management devices market include Sanofi S.A., Abbott Laboratories, Medtronic plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, i-SENS, Inc., Novo Nordisk A/S, Ypsomed Holding AG, Diabeloop SA., Tandem Diabetes Care, Inc. among others.
Key Developments
• In September 2023, Medtronic won the CE mark for the next-gen Simplera (CGM) continuous glucose monitor with InPen integration.
• In September 2022, Medtronic Plc launched the Smart MDI system which provides smart insulin dosing by combining the InPen smart insulin pen with the Guardian 4 smart continuous glucose monitoring (CGM) system.
Why Purchase the Report?
• To visualize the global smart insulin management devices market segmentation based on product type, disease type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of smart insulin management devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global smart insulin management devices market report would provide approximately 58 tables, 60 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Disease Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Increasing strategic developments by the companies
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Complications associated with insulin devices
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Insulin Pen Injectors*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Insulin jet injectors
7.4. Insulin pumps
7.4.1. External Insulin pumps
7.4.2. Implantable pumps
7.5. Insulin patches
7.6. Insulin inhalers
8. By Disease Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type
8.2. Diabetes Type I*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diabetes Type II
8.4. Gestational Diabetes
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Home Care settings
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Sanofi S.A.
12.1.1. Company Overview
12.1.2. Product Type Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Abbott Laboratories
12.3. Medtronic plc
12.4. Eli Lilly and Company
12.5. F. Hoffmann-La Roche Ltd
12.6. i-SENS, Inc.
12.7. Novo Nordisk A/S
12.8. Ypsomed Holding AG
12.9. Diabeloop SA.
12.10. Tandem Diabetes Care, Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Sanofi S.A., 4.	Key Developments, Abbott Laboratories, Medtronic plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, i-SENS, Inc., Novo Nordisk A/S, Ypsomed Holding AG, Diabeloop SA., Tandem Diabetes Care, Inc.

표 목록 (Tables)

List of Tables
Table 1 Global Smart Insulin Management Devices Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Smart Insulin Management Devices Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Smart Insulin Management Devices Market Value, By End-User , 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Smart Insulin Management Devices Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Smart Insulin Management Devices Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Smart Insulin Management Devices Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 7 Global Smart Insulin Management Devices Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Smart Insulin Management Devices Market Value, By Application, 2022-2033 (US$ Billion)
Table 9 Global Smart Insulin Management Devices Market Value, By End-User , 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Smart Insulin Management Devices Market Value, By End-User , 2022-2033 (US$ Billion)
Table 11 Global Smart Insulin Management Devices Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Smart Insulin Management Devices Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Smart Insulin Management Devices Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 14 North America Smart Insulin Management Devices Market Value, By Application, 2022-2033 (US$ Billion)
Table 15 North America Smart Insulin Management Devices Market Value, By End-User , 2022-2033 (US$ Billion)
Table 16 North America Smart Insulin Management Devices Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Smart Insulin Management Devices Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 18 Europe Smart Insulin Management Devices Market Value, By Application, 2022-2033 (US$ Billion)
Table 19 Europe Smart Insulin Management Devices Market Value, By End-User , 2022-2033 (US$ Billion)
Table 20 Europe Smart Insulin Management Devices Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Smart Insulin Management Devices Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Smart Insulin Management Devices Market Value, By Application, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Smart Insulin Management Devices Market Value, By End-User , 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Smart Insulin Management Devices Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Smart Insulin Management Devices Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 26 South America Smart Insulin Management Devices Market Value, By Application, 2022-2033 (US$ Billion)
Table 27 South America Smart Insulin Management Devices Market Value, By End-User , 2022-2033 (US$ Billion)
Table 28 South America Smart Insulin Management Devices Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Smart Insulin Management Devices Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Smart Insulin Management Devices Market Value, By Application, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Smart Insulin Management Devices Market Value, By End-User , 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Smart Insulin Management Devices Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Abbott: Overview
Table 34 Abbott: Product Portfolio
Table 35 Abbott: Key Developments
Table 36 Medtronic: Overview
Table 37 Medtronic: Product Portfolio
Table 38 Medtronic: Key Developments
Table 39 Tandem Diabetes Care, Inc.: Overview
Table 40 Tandem Diabetes Care, Inc.: Product Portfolio
Table 41 Tandem Diabetes Care, Inc.: Key Developments
Table 42 Insulet Corporation: Overview
Table 43 Insulet Corporation: Product Portfolio
Table 44 Insulet Corporation: Key Developments
Table 45 Eli Lilly and Company: Overview
Table 46 Eli Lilly and Company: Product Portfolio
Table 47 Eli Lilly and Company: Key Developments
Table 48 F. Hoffmann-La Roche Ltd: Overview
Table 49 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 50 F. Hoffmann-La Roche Ltd: Key Developments
Table 51 Novo Nordisk A/S: Overview
Table 52 Novo Nordisk A/S: Product Portfolio
Table 53 Novo Nordisk A/S: Key Developments
Table 54 Ypsomed AG: Overview
Table 55 Ypsomed AG: Product Portfolio
Table 56 Ypsomed AG: Key Developments
Table 57 i-SENS, Inc.: Overview
Table 58 i-SENS, Inc.: Product Portfolio
Table 59 i-SENS, Inc.: Key Developments
Table 60 Diabeloop SA: Overview
Table 61 Diabeloop SA: Product Portfolio
Table 62 Diabeloop SA: Key Developments

그림 목록 (Figures)

List of Figures
Figure 1 Global Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Smart Insulin Management Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Smart Insulin Management Devices Market Share, By Application, 2024 & 2033 (%)
Figure 4 Global Smart Insulin Management Devices Market Share, By End-User , 2024 & 2033 (%)
Figure 5 Global Smart Insulin Management Devices Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Smart Insulin Management Devices Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 7 Insulin Pen Injectors Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 8 Insulin Jet Injectors Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 9 Insulin Pumps Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 10 Insulin Patches Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 11 Others Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 12 Global Smart Insulin Management Devices Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 13 Type I Diabetes Application in Global Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 14 Type II Diabetes Application in Global Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 15 Gestational Diabetes Application in Global Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Smart Insulin Management Devices Market Y-o-Y Growth, By End-User , 2023-2033 (%)
Figure 17 Hospitals End-User in Global Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 18 Home Care settings End-User in Global Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 19 Specialty Clinics End-User in Global Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 20 Others End-User in Global Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Smart Insulin Management Devices Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Smart Insulin Management Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 24 North America Smart Insulin Management Devices Market Share, By Application, 2024 & 2033 (%)
Figure 25 North America Smart Insulin Management Devices Market Share, By End-User , 2024 & 2033 (%)
Figure 26 North America Smart Insulin Management Devices Market Share, By Country, 2024 & 2033 (%)
Figure 27 Europe Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 28 Europe Smart Insulin Management Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 29 Europe Smart Insulin Management Devices Market Share, By Application, 2024 & 2033 (%)
Figure 30 Europe Smart Insulin Management Devices Market Share, By End-User , 2024 & 2033 (%)
Figure 31 Europe Smart Insulin Management Devices Market Share, By Country, 2024 & 2033 (%)
Figure 32 Asia-Pacific Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 33 Asia-Pacific Smart Insulin Management Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Smart Insulin Management Devices Market Share, By Application, 2024 & 2033 (%)
Figure 35 Asia-Pacific Smart Insulin Management Devices Market Share, By End-User , 2024 & 2033 (%)
Figure 36 Asia-Pacific Smart Insulin Management Devices Market Share, By Country, 2024 & 2033 (%)
Figure 37 South America Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 38 South America Smart Insulin Management Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 39 South America Smart Insulin Management Devices Market Share, By Application, 2024 & 2033 (%)
Figure 40 South America Smart Insulin Management Devices Market Share, By End-User , 2024 & 2033 (%)
Figure 41 South America Smart Insulin Management Devices Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Smart Insulin Management Devices Market Value, 2022-2033 (US$ Billion)
Figure 43 Middle East and Africa Smart Insulin Management Devices Market Share, By Product Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Smart Insulin Management Devices Market Share, By Application, 2024 & 2033 (%)
Figure 45 Middle East and Africa Smart Insulin Management Devices Market Share, By End-User , 2024 & 2033 (%)
Figure 46 Abbott: Financials
Figure 47 Medtronic: Financials
Figure 48 Tandem Diabetes Care, Inc.: Financials
Figure 49 Insulet Corporation: Financials
Figure 50 Eli Lilly and Company: Financials
Figure 51 F. Hoffmann-La Roche Ltd: Financials
Figure 52 Novo Nordisk A/S: Financials
Figure 53 Ypsomed AG: Financials
Figure 54 i-SENS, Inc.: Financials
Figure 55 Diabeloop SA: Financials

글로벌 스마트 인슐린 관리 기기 시장 – 2023-2030

Global Smart Insulin Management Devices Market - 2023-2030